Discover our impact all over the world.

Numbers displayed on the map are a representation of the activity in each country. Once you use the filter selections below, you will have the opportunity to explore projects and faculty in each country.

Projects + Faculty = Activity Number



Projects 294
Countries 141
Faculty 349
Health Topics 123

Filter from the selections below

Clear All Filters

Advanced development and clinical evaluation of a synthetic intranasal Entamoeba histolytica vaccine containing adjuvant

This project proposes to optimize, manufacture, and clinically evaluate an intranasally delivered prophylactic Entamoeba histolytica vaccine (NIAID Category B pathogen) containing adjuvant. The proposed vaccine consists of a synthetic recombinant protein antigen (LecA) and a synthetic dual TLR ligand adjuvant formulation (GLA-3M052 liposomes) administered by nasal spray. The scope of work is designed to optimize dose and excipient composition and intranasal administration of the candidate product in preclinical models followed by cGMP manufacture and a Phase 1 clinical trial. By implementing critical product enhancement strategies and cutting edge adjuvant technology early in development, a vaccine against the enteric Category B pathogen E. histolytica will be developed that is able to overcome many of the challenges associated with traditional enteric vaccine approaches. In particular, we will seek to establish the safety and immunogenicity of intranasal delivery of a recombinant antigen-based vaccine containing a synthetic adjuvant formulation.

Active Dates 
09/01/2018 to 06/30/2025
Faculty Involved